📊 OFIX Key Takeaways
Is Orthofix Medical Inc. (OFIX) a Good Investment?
Despite massive revenue growth and exceptional 70.9% gross margins, Orthofix is fundamentally broken on profitability and cash generation. The company is burning -28.3M in annual free cash flow and posting -14.4M operating losses, signaling severe operational inefficiency that cannot be masked by strong product margins. While the balance sheet provides runway and debt ratios are manageable, continued negative cash burn threatens long-term viability without demonstrated path to profitability.
Orthofix exhibits strong gross margins and solid liquidity with modest leverage, but it remains unprofitable as operating costs and integration-related expenses suppress margins. Revenue scale has expanded sharply and operating cash flow is positive, leaving free cash flow near breakeven. Achieving sustainable profitability hinges on cost discipline and realizing synergies to convert gross margin strength into positive EBIT and FCF.
Why Buy Orthofix Medical Inc. Stock? OFIX Key Strengths
- Exceptional gross margin of 70.9% indicates strong underlying product economics
- Strong liquidity position with 2.87x current ratio and 120.3M cash providing operational runway
- Reasonable debt-to-equity ratio of 0.51x with manageable leverage structure
- Improving EPS trend showing 29.4% YoY improvement in loss per share
- High gross margin (68.8%) supporting unit economics
- Healthy liquidity and moderate leverage (2.45x current; 0.35x D/E)
- Positive operating cash flow with improving net losses
OFIX Stock Risks: Orthofix Medical Inc. Investment Risks
- Critical negative free cash flow of -28.3M annually indicating company is burning cash despite revenue growth
- Severe operating profitability gap: 70.9% gross margin fails to generate positive operating income (-7.3% margin), suggesting uncontrolled SG&A expenses
- Negative operating cash flow of -17.6M combined with negative net income indicates conversion problems from accrual to actual cash
- Unsustainable 4802% YoY revenue growth likely driven by acquisition, masking underlying operational challenges
- At current burn rate, 120.3M cash runway will deplete within 4-5 years without achieving operating breakeven
- Persistent operating losses and deeply negative interest coverage
- Integration/efficiency execution risk keeping opex elevated
- Thin/negative FCF leaves limited cushion if OCF softens or capex rises
Key Metrics to Watch
- Quarterly operating cash flow trajectory toward positive territory
- Operating margin expansion and path to profitability with current revenue base
- Free cash flow improvement and timeline to cash flow breakeven
- SG&A expense ratio and operating leverage realization from revenue base
- Operating margin (EBIT) progression toward positive
- Sustained positive free cash flow
Orthofix Medical Inc. (OFIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.87x current ratio provides a solid financial cushion.
OFIX Profit Margin, ROE & Profitability Analysis
OFIX vs Healthcare Sector: How Orthofix Medical Inc. Compares
How Orthofix Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Orthofix Medical Inc. Stock Overvalued? OFIX Valuation Analysis 2026
Based on fundamental analysis, Orthofix Medical Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Orthofix Medical Inc. Balance Sheet: OFIX Debt, Cash & Liquidity
OFIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Orthofix Medical Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-4.12 indicates the company is currently unprofitable.
OFIX Revenue Growth, EPS Growth & YoY Performance
OFIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $193.6M | -$20.9M | $-0.52 |
| Q3 2025 | $196.6M | -$14.1M | $-0.57 |
| Q2 2025 | $198.6M | -$14.1M | $-0.36 |
| Q1 2025 | $188.6M | -$36.0M | $-0.95 |
| Q3 2024 | $184.0M | -$27.4M | $-0.71 |
| Q2 2024 | $187.0M | -$33.4M | $-0.88 |
| Q1 2024 | $175.2M | -$36.0M | $-0.95 |
| Q3 2023 | $114.0M | $2.5M | $-0.53 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Orthofix Medical Inc. Dividends, Buybacks & Capital Allocation
OFIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Orthofix Medical Inc. (CIK: 0000884624)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OFIX
What is the AI rating for OFIX?
Orthofix Medical Inc. (OFIX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OFIX's key strengths?
Claude: Exceptional gross margin of 70.9% indicates strong underlying product economics. Strong liquidity position with 2.87x current ratio and 120.3M cash providing operational runway. ChatGPT: High gross margin (68.8%) supporting unit economics. Healthy liquidity and moderate leverage (2.45x current; 0.35x D/E).
What are the risks of investing in OFIX?
Claude: Critical negative free cash flow of -28.3M annually indicating company is burning cash despite revenue growth. Severe operating profitability gap: 70.9% gross margin fails to generate positive operating income (-7.3% margin), suggesting uncontrolled SG&A expenses. ChatGPT: Persistent operating losses and deeply negative interest coverage. Integration/efficiency execution risk keeping opex elevated.
What is OFIX's revenue and growth?
Orthofix Medical Inc. reported revenue of $196.7M.
Does OFIX pay dividends?
Orthofix Medical Inc. does not currently pay dividends.
Where can I find OFIX SEC filings?
Official SEC filings for Orthofix Medical Inc. (CIK: 0000884624) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OFIX's EPS?
Orthofix Medical Inc. has a diluted EPS of $-0.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OFIX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Orthofix Medical Inc. has a SELL rating with 71% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OFIX stock overvalued or undervalued?
Valuation metrics for OFIX: ROE of -4.8% (sector avg: 15%), net margin of -10.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OFIX stock in 2026?
Our dual AI analysis gives Orthofix Medical Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OFIX's free cash flow?
Orthofix Medical Inc.'s operating cash flow is $-17.6M, with capital expenditures of $10.7M. FCF margin is -14.4%.
How does OFIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10.6% (avg: 12%), ROE -4.8% (avg: 15%), current ratio 2.87 (avg: 2).